In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltech's New Wherewithal

Executive Summary

Britain's original biotech company, Celltech Group PLC, has lately made some strategic moves that make it the biggest biotech firm in all of Europe. The firm has been acquiring discovery, regulatory and marketing assets that will, it hopes, allow it to keep more of the value of its own antibody-based products. Celltech was able to do its acquisitions inexpensively, for stock, because the firms it bought were in trouble and poorly valued by the market. Their assets bring Celltech more potential than it has ever had. Big Pharma partnerships are still an option, but not a necessity. Celltech's challenge going forward is to integrate the new businesses, so they work well together. Even analysts clearly bullish on the company acknowledge the difficulty of the tasks awaiting management. Celltech, now in the spotlight as Europe's biggest biotech firm, possesses size and seniority. But neither will make it a market leader. Celltech must now successfully execute on tasks it has never before attempted.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel